Phase II Combination Steroid and Anti-VEGF for Persistent DME



Status:Completed
Conditions:Cardiology, Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:9/27/2018
Start Date:February 2014
End Date:June 5, 2017

Use our guide to learn which trials are right for you!

Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy

Although anti-vascular endothelial growth factor (VEGF) therapy is generally effective as
treatment for center-involved diabetic macular edema (DME), a substantial proportion of
anti-VEGF-treated eyes with DME do not achieve vision of 20/20 or complete resolution of
retinal thickening. Indeed, over 50% of ranibizumab-treated eyes did not achieve a 2 or more
line improvement in visual acuity from baseline at 2 years in Protocol I, a previous DRCR.net
(Diabetic Retinopathy Clinical Research Network) study. Furthermore, 27% of
ranibizumab-treated eyes still had central subfield (CSF) thickness on time-domain optical
coherence tomography (OCT) ≥ 300 at 1 year, and more than 40% of ranibizumab-treated eyes did
not achieve complete resolution of retinal thickening (< 250 microns) by 2 years. Thus, there
is a need for alternative or additional treatments that will improve vision by reducing
retinal edema in eyes with persistent DME following previous anti-VEGF therapy. Intravitreal
steroid is not as efficacious as ranibizumab in eyes with DME overall, but it has been shown
to have a positive effect for DME in some eyes and might add benefit in eyes that are already
receiving anti-VEGF.

The main objective of this study is to assess the short-term effects of combination
steroid+anti-VEGF therapy on visual acuity and retinal thickness on OCT in comparison with
that of continued anti-VEGF therapy alone in eyes with persistent central-involved DME and
visual acuity impairment despite previous anti-VEGF treatment. This study will provide
important information for the design of a future confirmatory phase III clinical trial on the
efficacy of combination steroid and anti-VEGF in eyes with persistent DME and vision
impairment following previous anti-VEGF therapy. The primary outcome for efficacy will be the
mean change in visual acuity at 24 weeks.

Each study eye is required to complete a 12-week run-in phase. The run-in phase will identify
study eyes that truly have persistent DME despite anti-VEGF therapy by requiring an
additional 3 injections while also collecting standardized visual acuity and OCT
measurements. At the enrollment, 4-week and 8-week visits of the run-in phase, enrolled eyes
will receive an intravitreal injection of ranibizumab 3mg. Then at the 12-week run-in visit,
if the eye still has persistent DME, it will be randomized to receive either intravitreal
sham+intravitreal ranibizumab 0.3 or intravitreal dexamethasone+intravitreal ranibizumab 0.3
injections. The randomized study duration is 24 week, during which a protocol visit takes
place every month. The combination injections of sham+ranibizumab or dexamethasone
+ranibizumab will be given at the randomization visit (baseline) and at the 12-week visit
after randomization. In between, an intravitreal injection of ranibizumab only will be given
to study eyes at the 4, 8, 16 and 20 week visits.


Inclusion Criteria:

1. Age ≥ 18 years i) Individuals <18 years old are not being included because DME is so
rare in this age group that the diagnosis of DME may be questionable.

2. Diagnosis of diabetes mellitus (type 1 or type 2)

3. Any one of the following will be considered to be sufficient evidence that diabetes is
present:

1. Current regular use of insulin for the treatment of diabetes

2. Current regular use of oral anti-hyperglycemia agents for the treatment of
diabetes

3. Documented diabetes by ADA (American Diabetes Association) and/or WHO (World
Health Organization) criteria

4. At least one eye meets the study eye criteria listed below.

5. Fellow eye (if not a study eye) meets criteria.

6. Able and willing to provide informed consent.

Meets all of the following ocular criteria in at least the one eye:

1. At least 3 injections of anti-VEGF drug (ranibizumab, bevacizumab, or aflibercept)
within the prior 20 weeks.

2. Visual acuity letter score in study eye ≤ 78 and ≥24 (approximate Snellen equivalent
20/32 to 20/320).

3. On clinical exam, definite retinal thickening due to DME involving the center of the
macula.

4. OCT CSF thickness, within 8 days of enrollment:

i) On Zeiss Cirrus ≥ 290 microns in women; ≥ 305 in men ii) On Heidelberg Spectralis:
≥ 305 microns in women; ≥ 320 in men

5. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate
OCTs.

Exclusion Criteria:

An individual is not eligible if any of the following exclusion criteria are present:

1. History of chronic renal failure requiring dialysis or kidney transplant.

2. A condition that, in the opinion of the investigator, would preclude participation in
the study (e.g., unstable medical status including blood pressure, cardiovascular
disease, and glycemic control).

3. Initiation of intensive insulin treatment (a pump or multiple daily injections) within
4 months prior to randomization or plans to do so in the next 4 months.

4. Participation in an investigational trial within 30 days of enrollment that involved
treatment with any drug that has not received regulatory approval for the indication
being studied. Note: study participants cannot receive another investigational drug
while participating in the study.

5. Known allergy to any component of the study drugs (including povidone iodine prep).

6. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood
pressure is brought below 180/110 by anti-hypertensive treatment, the individual can
become eligible.

7. Myocardial infarction, other acute cardiac event requiring hospitalization, stroke,
transient ischemic attack, or treatment for acute congestive heart failure within 1
month prior to enrollment.

8. Systemic steroid, anti-VEGF or pro-VEGF treatment within 4 months prior to enrollment
or anticipated use during the study. These drugs cannot be used during the study.

9. For women of child-bearing potential: pregnant or lactating or intending to become
pregnant within the next 9 months. Women who are potential study participants should
be questioned about the potential for pregnancy. Investigator judgment is used to
determine when a pregnancy test is needed.

10. Individual is expecting to move out of the area of the clinical center to an area not
covered by another clinical center during the next 9 months.

The following exclusions apply to the study eye only (i.e., they may be present for the
non-study eye unless otherwise specified):

1. Macular edema is considered to be due to a cause other than DME. An eye should not be
considered eligible if: (1) the macular edema is considered to be related to ocular
surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that
vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal
membrane) are the primary cause of the macular edema.

2. An ocular condition is present such that, in the opinion of the investigator, visual
acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy,
pigment abnormalities, dense subfoveal hard exudates, non-retinal condition, etc.).

3. An ocular condition is present (other than DME) that, in the opinion of the
investigator, might affect macular edema or alter visual acuity during the course of
the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease,
neovascular glaucoma, etc.).

4. Substantial posterior capsule opacity that, in the opinion of the investigator, is
likely to be decreasing visual acuity by 3 lines or more (i.e., opacity would be
reducing acuity to 20/40 or worse if eye was otherwise normal).

5. History of intravitreal anti-VEGF drug within 21 days prior to enrollment.

6. History of intravitreal or peribulbar corticosteroids within 3 months prior to
enrollment.

7. History of macular laser photocoagulation within 4 months prior to enrollment.

8. History of panretinal (scatter) photocoagulation (PRP) within 4 months prior to
enrollment or anticipated need for PRP in the 6 months following enrollment into
run-in phase.

9. Any history of vitrectomy.
We found this trial at
56
sites
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
Phone: 206-543-7250
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Phone: 585-275-4141
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Amarillo, Texas 79106
Phone: 806-351-1870
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Augusta, Georgia 30909
Phone: 706-650-0061
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Austin, Texas 78705
Phone: 512-451-0103
?
mi
from
Austin, TX
Click here to add this to my saved trials
Austin, Texas 78705
Phone: 512-454-0138
?
mi
from
Austin, TX
Click here to add this to my saved trials
Baltimore, Maryland 21237
Phone: 410-686-3394
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Beachwood, Ohio 44122
Phone: 216-831-5700
?
mi
from
Beachwood, OH
Click here to add this to my saved trials
Bethesda, Maryland 20892
Principal Investigator: Emily Chew, MD
Phone: 301-496-6583
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Beverly Hills, California 90211
Phone: 310-854-6201
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Boston, Massachusetts 02114
Phone: 617-367-4800
?
mi
from
Boston, MA
Click here to add this to my saved trials
One Joslin Place
Boston, Massachusetts 02215
617-309-2400
Principal Investigator: George S. Sharuk, MD
Phone: 614-309-2520
Joslin Diabetes Center Joslin Diabetes Center, located in Boston, Massachusetts, is the world's largest diabetes...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charlotte, North Carolina 28210
Principal Investigator: David Browning, MD
Phone: 704-295-3390
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dubuque, Iowa 52001
?
mi
from
Dubuque, IA
Click here to add this to my saved trials
Fort Myers, Florida 33912
Phone: 239-939-4323
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Grand Blanc, Michigan
Phone: 810-694-6933
?
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Grand Rapids, Michigan
Phone: 616-954-2020
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Houston, Texas 77025
Phone: 713-799-9975
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-524-3434
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Huntington Beach, California 92647
?
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Indianapolis, Indiana 46290
Principal Investigator: Raj K Maturi, MD
Phone: 317-817-1414
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville, Florida 32209
Phone: 904-244-9361
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Knoxville, Tennessee 37909
Principal Investigator: Joseph M. Googe, MD
Phone: 865-588-0811
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lakeland, Florida 33805
Phone: 863-682-7474
?
mi
from
Lakeland, FL
Click here to add this to my saved trials
Leesburg, Virginia 20176
Principal Investigator: Sam E Mansour, MD
Phone: 540-349-1882
?
mi
from
Leesburg, VA
Click here to add this to my saved trials
Loma Linda, California 92354
Phone: 909-558-2169
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Lubbock, Texas 79424
Phone: 806-792-0066
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Madison, Wisconsin 53705
Phone: 608-263-7290
?
mi
from
Madison, WI
Click here to add this to my saved trials
McAllen, Texas 78503
Principal Investigator: Victor H Gonzalez, MD
Phone: 956-631-8875
?
mi
from
McAllen, TX
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
Phone: 612-871-2292
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Mountain View, California 94040
?
mi
from
Mountain View, CA
Click here to add this to my saved trials
400 Bayonet Street
New London, Connecticut 06320
?
mi
from
New London, CT
Click here to add this to my saved trials
New York, New York 10021
Phone: 212-439-9600
?
mi
from
New York, NY
Click here to add this to my saved trials
Newark, New Jersey 07103
Phone: 973-972-2032
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Norwich, Connecticut 06360
Phone: 860-887-6429
?
mi
from
Norwich, CT
Click here to add this to my saved trials
Ocala, Florida 34474
Phone: 352-622-5183
?
mi
from
Ocala, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Phone: 215-662-9702
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Portland, Oregon 97210
Principal Investigator: Mark A Peters, MD
Phone: 503-274-2121
?
mi
from
Portland, OR
Click here to add this to my saved trials
Portland, Oregon 97239
Phone: 503-494-3055
?
mi
from
Portland, OR
Click here to add this to my saved trials
Redlands, California 92374
Phone: 909-796-3003
?
mi
from
Redlands, CA
Click here to add this to my saved trials
Richmond, Virginia
Phone: 804-644-7478
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Rochester, New York 14618
Phone: 585-442-3411
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Sacramento, California 95819
Phone: 916-339-3655
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salt Lake City, Utah
Phone: 801-312-2020
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Antonio, Texas 78240
Principal Investigator: Calvin E Mein, MD
Phone: 210-615-1311
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Sandy Springs, Georgia 30328
?
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
Santa Barbara, California 93103
Phone: 805-963-1648
?
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Sarasota, Florida 34239
Phone: 941-921-5335
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Shawnee Mission, Kansas 66204
?
mi
from
Shawnee Mission, KS
Click here to add this to my saved trials
Spokane, Washington 99204
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Tampa, Florida 33609
Phone: 813-875-6373
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Walnut Creek, California 94598
Phone: 925-943-6800
?
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
West Des Moines, Iowa 50266
Phone: 515-223-8685
?
mi
from
West Des Moines, IA
Click here to add this to my saved trials